MacDonald Sarah C, Cohen Jacqueline M, Panchaud Alice, McElrath Thomas F, Huybrechts Krista F, Hernández-Díaz Sonia
Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.
Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
Pharmacoepidemiol Drug Saf. 2019 Sep;28(9):1211-1221. doi: 10.1002/pds.4794. Epub 2019 Jul 22.
The purpose of the study is to develop an algorithm to identify pregnancies in administrative databases and apply it to assess pregnancy rates and outcomes in women prescribed isotretinoin or tretinoin.
Using the 2011 to 2015 Truven Health MarketScan Database, we identified pregnancies, including losses and terminations. In a cohort design, nonpregnant women filling a prescription for isotretinoin or tretinoin were matched to five women without either prescription. Women were followed for 365 days or until conception, medication discontinuation, or enrollment discontinuation ("prescription episode"). Rates of pregnancy, risks of pregnancy losses, and prevalence of infant malformations at birth were assessed by exposure.
We identified 2 179 192 livebirths, 8434 stillbirths, 2521 mixed births, 415 110 spontaneous abortions, 124 556 elective terminations, and 8974 unspecified abortions. There were 86 834 isotretinoin and 973 587 tretinoin episodes, matched to 5 302 105 unexposed women. Pregnancy rates were 3 (isotretinoin), 19 (tretinoin), and 34 (unexposed) per 1000 person-years. Risk of spontaneous pregnancy losses were similar; however, terminations were more common in the isotretinoin-exposed (28% [95% CI: 21%-36%]) than the tretinoin-exposed (10% [95% CI: 9%-11%]) or unexposed pregnancies (6%). Malformations occurred in 4.5% (95% CI: 3.5%-5.6%) of the tretinoin-exposed pregnancies and 4.2% of the unexposed pregnancies (adjusted odds ratio: 1.16 [95% CI: 0.85-1.58]); isotretinoin-exposed births were too few to assess malformations.
Administrative databases can complement risk evaluation and mitigation strategies (REMS) for known teratogens and contribute to safety surveillance for other medications. Here, isotretinoin-exposed pregnancy rates were low, but existent, and many pregnancies were terminated. Tretinoin exposure was not associated with a meaningfully elevated risk of losses or malformations as compared with unexposed pregnancies.
本研究旨在开发一种算法,用于在管理数据库中识别妊娠情况,并将其应用于评估服用异维甲酸或维甲酸的女性的妊娠率及妊娠结局。
利用2011年至2015年的Truven Health MarketScan数据库,我们识别出了妊娠情况,包括流产和终止妊娠。在一项队列设计中,为开具异维甲酸或维甲酸处方的非妊娠女性匹配了五名未开具任何一种处方的女性。对女性进行365天的随访,或直至怀孕、停药或退出研究(“处方期”)。通过暴露情况评估妊娠率、流产风险以及出生时婴儿畸形的患病率。
我们识别出2179192例活产、8434例死产、2521例混合产、415110例自然流产、124556例选择性终止妊娠以及8974例未明确说明的流产。有86834例异维甲酸处方期和973587例维甲酸处方期,与5302105例未暴露女性相匹配。妊娠率分别为每1000人年3例(异维甲酸)、19例(维甲酸)和34例(未暴露)。自然流产风险相似;然而,异维甲酸暴露组的终止妊娠情况(28%[95%置信区间:21%-36%])比维甲酸暴露组(10%[95%置信区间:9%-11%])或未暴露组妊娠(6%)更为常见。维甲酸暴露的妊娠中有4.5%(95%置信区间:3.5%-5.6%)出现畸形,未暴露妊娠中有4.2%出现畸形(调整后的优势比:1.16[95%置信区间:0.85-1.58]);异维甲酸暴露的出生案例过少,无法评估畸形情况。
管理数据库可以补充已知致畸剂的风险评估和缓解策略(REMS),并有助于其他药物的安全监测。在此,异维甲酸暴露的妊娠率较低,但确实存在,且许多妊娠被终止。与未暴露妊娠相比,维甲酸暴露与流产或畸形风险的显著升高无关。